Original research
by
Gahrton, Caroline et al
Release Date
2024
Geography
Sweden
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
With the introduction of a needle syringe program (NSP) in Stockholm, Sweden and unrestricted availability of direct acting antiviral (DAA) treatment, we investigate the change of prevalence and incidence of HCV infection among people who inject drugs (PWID) over time.
Findings/Key points
The prevalence of viremic HCV infection decreased from 62% to 30% year 2013-2021 while the prevalence of cured after treatment increased from 0 to 22%, corresponding to 42% cured after treatment out of those eligible in 2021.
Design/methods
All persons attending the Stockholm Needle Syringe Program 2013-2021 (n=4,138) were included.
Keywords
About PWUD
Harm reduction
Injecting drugs
Social benefits
